| HOME >> BIOLOGY >> TECHNOLOGY |
Koplan, M.D., will present a meta-analysis comparing bi-ventricular
pacing percentages and its impact on the combined risk of death and
heart failure hospitalization. The results will be presented at 9:00
a.m., during an oral abstract session in Room S403.
Tuesday, April 1
-- TAXUS Stent in Large Vessels. David A. Cox, M.D., will present an
analysis of data from the TAXUS IV & V randomized clinical trials
comparing the outcomes of drug-eluting stents versus bare-metal stents
in patients with large vessels. The results will be presented at
8:30 a.m., during an oral abstract session in Room S103d.
-- TAXUS IV/V Diabetic data. Gregg W. Stone, M.D., will present
three-year results from a pooled analysis of the TAXUS IV & V clinical
trials, including angiographic and IVUS outcomes at nine months and
clinical outcomes at three years for 317 diabetic patients and 862
non-diabetic patients. The goal of the study is to determine if
diabetes is a risk factor for restenosis and adverse clinical outcomes
in patients treated with the TAXUS Stent. The results will be
presented at 9:31 a.m., during an oral abstract session in Room S103d.
The Company plans to issue a press release at this time.
-- TAXUS Stent TLR meta-analysis. Stephen G. Ellis, M.D., will present a
meta-analysis of long-term follow-up data from more than 1,300 patients
in the TAXUS clinical trial program with up to five years of follow-up.
The study is designed to determine predictors of target lesion
revascularization (TLR) and long-term outcomes in drug-eluting stent
patients who develop in-stent restenosis. The results will be
presented at 9:43 a.m., during an oral abstract session in Room S103d.
The Company plans to issue a press release at this t
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |